Proceedings of the National Academy of Sciences 123, e2603905123 (2026).
Proceedings of the National Academy of Sciences 123, e2603905123 (2026).
B cell imprinting in children impairs antibodies to the haemagglutinin stalk
Nature 653, 528–537 (2026).
✦ Author interview at BRIC Distinguished Korean Scientists
Nature Communications 16, 7067 (2025).
✤ Editors’ Highlights in Nature Communications, Microbiology and infectious diseases
✤ Featured in Trends in Microbiology — “On target: antibodies against the neuraminidase active site” (2025)
✦ Author interview at BRIC Distinguished Korean Scientists
Nature Communications 12, 6287 (2021).
✦ Author interview at BRIC Distinguished Korean Scientists
AI-based HIV-1 Env designs devoid of gp41 mimic native gp120 pre-fusion Env In preparation
In preparation.
Structural and genetic basis of influenza hemagglutinin anchor epitope recognition guides antibody and immunogen design Under review
Under review.
Proceedings of the National Academy of Sciences 123, e2603905123 (2026).
B cell imprinting in children impairs antibodies to the haemagglutinin stalk
Nature 653, 528–537 (2026).
✦ Author interview at BRIC Distinguished Korean Scientists
Cell Host & Microbe 34, 873–887.e11 (2026).
Nature Communications 16, 7067 (2025).
✤ Editors’ Highlights in Nature Communications, Microbiology and infectious diseases
✤ Featured in Trends in Microbiology — “On target: antibodies against the neuraminidase active site” (2025)
✦ Author interview at BRIC Distinguished Korean Scientists
Nature Communications 16, 10250 (2025).
Single-molecule fingerprinting of protein–drug interaction using a funneled biological nanopore
Nature Communications 14, 1461 (2023).
Nature Communications 12, 6287 (2021).
✦ Author interview at BRIC Distinguished Korean Scientists
Angewandte Chemie International Edition 59, 23244–23251 (2020).
Journal of Microbiology and Biotechnology 30, 1760–1768 (2020).
Journal of Microbiology and Biotechnology 28, 2113–2120 (2018).
Journal of Microbiology and Biotechnology 28, 1376–1383 (2018).
Biotechnology and Bioprocess Engineering 22, 114–119 (2017).
Tie2 agonistic antibodies and uses thereof
PCT WO2022235090A1 (2022).
Granted: JP 7774076 (2025), AU 2022271112 (2026) · Pending: US, EP, CN, CA, KR
§ Technology transferred to INGENIA Therapeutics; under development as a therapeutic antibody for ophthalmic diseases.
PCT WO2022265264A1 (2022).
Granted: KR 10-2680147 (2024) · Pending: US, EP, JP, CN
§ Technology transferred to ApitBio; under development as a therapeutic antibody for HBV infection.